OTCMKTS:RHHBY - Roche Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $48.00
  • Forecasted Upside: 20.03 %
  • Number of Analysts: 14
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$39.99
▼ -0.21 (-0.52%)
1 month | 3 months | 12 months
Get New Roche Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RHHBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RHHBY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$48.00
▲ +20.03% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Roche in the last 3 months. The average price target is $48.00, with a high forecast of $48.00 and a low forecast of $48.00. The average price target represents a 20.03% upside from the last price of $39.99.
Buy
The current consensus among 14 contributing investment analysts is to buy stock in Roche.

Past Monthly Recommendations

Move your mouse over past months for details

  • 1 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/10/2019
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
8/8/2019
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/6/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/4/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/4/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 1 sell ratings
8/2/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/1/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/31/2020

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetDetails
10/16/2020UBS GroupReiterated RatingBuy
i
9/29/2020Berenberg BankInitiated CoverageHold
i
9/28/2020Societe GeneraleReiterated RatingBuy
i
8/18/2020Morgan StanleyReiterated RatingOverweight
i
7/29/2020UBS GroupReiterated RatingBuy
i
7/29/2020Morgan StanleyReiterated RatingOverweight
i
7/13/2020Sanford C. BernsteinInitiated CoverageOutperform
i
7/3/2020AlphaValueUpgradeReduce
i
5/15/2020BarclaysReiterated RatingOverweight
i
5/13/2020Wolfe ResearchUpgradeMarket Perform ➝ Outperform
i
4/30/2020HSBCUpgradeReduce ➝ Hold
i
4/28/2020UBS GroupReiterated RatingBuy
i
4/28/2020Morgan StanleyReiterated RatingOverweight
i
4/23/2020JPMorgan Chase & Co.Reiterated RatingOverweight
i
3/10/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
i
2/18/2020CitigroupUpgradeNeutral ➝ Buy
i
1/23/2020CowenInitiated CoverageBuy$48.00
i
Rating by Steve Scala at Cowen Inc
12/23/2019CowenReiterated RatingBuy$42.00
i
12/23/2019Royal Bank of CanadaReiterated RatingOutperform
i
7/26/2019UBS GroupUpgradeNeutral ➝ Buy
i
6/20/2019Liberum CapitalDowngradeBuy ➝ Hold
i
6/20/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
i
1/28/2019Credit Suisse GroupUpgradeUnderperform ➝ Neutral
i
1/28/2019ArgusInitiated CoverageBuy ➝ Buy
i
12/11/2018Jefferies Financial GroupReiterated RatingBuy ➝ Buy
i
11/26/2018CitigroupReiterated RatingHold
i
Rating by Andrew Baum at Citigroup Inc.
11/19/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy
i
10/23/2018Wolfe ResearchInitiated CoverageMarket Perform
i
9/10/2018Bank of AmericaDowngradeBuy ➝ Neutral
i
7/26/2018CowenReiterated RatingBuy$34.00
i
5/25/2018Credit Suisse GroupReiterated RatingNeutral ➝ Underperform
i
5/10/2018Sanford C. BernsteinDowngradeOutperform ➝ Market Perform
i
3/27/2018Morgan StanleyDowngradeEqual Weight ➝ Underweight
i
1/15/2018Societe GeneraleDowngradeHold ➝ Sell
i
12/29/2017JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight
i
12/7/2017Piper Jaffray CompaniesReiterated RatingBuy
i
10/24/2017Berenberg BankDowngradeBuy ➝ Hold
i
10/18/2017CitigroupDowngradeBuy ➝ Neutral
i
9/26/2017BNP ParibasDowngradeNeutral ➝ Underperform
i
9/19/2017CowenReiterated RatingBuy$38.00
i
Rating by Steve Scala at Cowen Inc
8/14/2017CowenSet Price TargetBuy$38.00
i
Rating by Steve Scala at Cowen Inc
7/26/2017Morgan StanleyReiterated RatingOverweight ➝ Equal Weight
i
7/10/2017CowenSet Price TargetBuy$38.00
i
Rating by Steve Scala at Cowen Inc
7/7/2017Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
i
7/6/2017UBS GroupDowngradeBuy ➝ Neutral
i
6/30/2017Societe GeneraleDowngradeBuy ➝ Hold
i
6/20/2017BNP ParibasReiterated RatingOutperform ➝ Neutral
i
4/5/2017CowenUpgradeMarket Perform ➝ Outperform$35.00 ➝ $38.00
i
3/9/2017Liberum CapitalInitiated CoverageHold ➝ Hold
i
3/7/2017BarclaysInitiated CoverageOverweight
i
2/19/2017Jefferies Financial GroupReiterated RatingBuy
i
12/7/2016Sanford C. BernsteinReiterated RatingOverweight
i
8/3/2016CitigroupReiterated RatingBuy
i
5/13/2016Jefferies Financial GroupReiterated RatingBuy
i
4/1/2016CitigroupReiterated RatingBuy
i
1/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight
i
12/2/2015CitigroupUpgradeNeutral ➝ Buy
i
(Data available from 10/31/2015 forward)
Roche logo
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Further, the company discovers, develops, and delivers gene therapies. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $39.99
$39.72
$40.15

50 Day Range

MA: $43.62
$40.09
$46.84

52 Week Range

Now: $39.99
$35.04
$47.15

Volume

1,180,392 shs

Average Volume

1,815,591 shs

Market Capitalization

$273.87 billion

P/E Ratio

15.74

Dividend Yield

1.79%

Beta

0.32